Trademarkia Logo

Canada

C$
Trademark Search in Canada
Liminal BioSciences & Design

View On IC.GC.CA

Liminal BioSciences & Design
REGISTERED

on 31 May 2023

Last Applicant/ Owned by

Liminal BioSciences Inc.

231 Dundas St EBelleville

ONTARIO

CA

K8N1E2

Serial Number

1990946 filed on 17th Oct 2019

Registration Number

TMA1182327 registered on 31st May 2023

Registration expiry Date

31st May 2033

Correspondent Address

PERLEY-ROBERTSON, HILL & MCDOUGALL LLP

1400 - 340 ALBERT STREETOTTAWA

ONTARIO

CA

K1R0A5

Liminal BioSciences & Design

Trademark usage description

inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; Read More

Vienna Information

26 . 3 . 4

Several triangles, juxtaposed, joined or intersectingPlusieurs triangles, juxtaposés, accolés ou se coupant

26 . 3 . 7

Triangular figures with one or more truncated or rounded anglesFigures triangulaires à un ou plusieurs angles coupés ou arrondis

26 . 3 . 5

Triangles pointing downwardsTriangles avec la pointe en bas

26 . 11 . 1

One line or one bandUne ligne ou une bande

26 . 11 . 7

Vertical lines or bandsLignes ou bandes verticales

26 . 11 . 10

Straight lines or bandsLignes ou bandes droites

29 . 1 . 3

GreenVert

29 . 1 . 4

BlueBleu

29 . 1 . 6

White, grey, silverBlanc, gris, argent

Classification Information

Class [005]
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis

Classification kind code

11

Class [035]
Developing marketing strategies and marketing concepts for others

Classification kind code

11

Class [036]
Providing information in insurance matters; providing insurance information; providing insurance information and consultancy

Classification kind code

11

Class [040]
Assembly of pharmaceuticals for others

Classification kind code

11

Class [042]
Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals

Classification kind code

11

Class [044]
Pharmaceutical advice; pharmaceutical consultancy services; provision of pharmaceutical information; providing information to patients in the field of administering medications; medical care and analysis services relating to patient treatment

Classification kind code

11

Class [045]
Providing personal support services for families of patients with life threatening disorders; providing companionship services for families of patients with life threatening disorders

Classification kind code

11

Mark Details

Serial Number

1990946

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 42
on 8th Mar 2023		Advertised
Submitted for opposition 27
on 13th Feb 2023		Approval Notice Sent
Submitted for opposition 26
on 13th Feb 2023		Approved
Submitted for opposition 22
on 27th Jul 2022		Search Recorded
Submitted for opposition 20
on 27th Jul 2022		Examiner's First Report
Submitted for opposition 287
on 24th Mar 2022		Pre-Assessment Letter Sent
Submitted for opposition 48
on 11th Jun 2020		Agent Changed
Submitted for opposition 31
on 31st Oct 2019		Formalized
Submitted for opposition 1
on 18th Oct 2019		Created
Submitted for opposition 30
on 17th Oct 2019		Filed